Observational study of durvalumab in patients with non-small-cell lung cancer in the United Kingdom

Trial Identifier: D4191R00038
Start Date:June 2021
Primary Completion Date: September 2022
Study Completion Date: September 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

United Kingdom Canterbury, United Kingdom, CT1 3NG
United Kingdom Cardiff, United Kingdom, CF14 2TL
United Kingdom Harrogate, United Kingdom, HG2 7SX
United Kingdom Leeds, United Kingdom, LS9 7TF
United Kingdom London, United Kingdom, SW3 6JJ
United Kingdom London, United Kingdom, SE1 9RT
United Kingdom Manchester, United Kingdom, M20 4BX
United Kingdom Portsmouth, United Kingdom, PO6 3LY
United Kingdom Taunton, United Kingdom, TA1 5DA
United Kingdom Truro, United Kingdom, TR1 3LJ